Last reviewed · How we verify
NCT06078215: CERBERUS
CERebrolysine Effect on Blood-brain Barrier in acUte Ischemic Stroke
Phase 4 trial testing Cerebrolysin in Acute Ischemic Stroke in 350 participants. Status unknown.
31 January 2025
Quick facts
| Lead sponsor | Poznan University of Medical Sciences |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 350 |
| Start date | 10 January 2023 |
| Primary completion | 31 January 2025 |
| Estimated completion | 31 March 2025 |
| Sites | 1 location across Poland |
Drugs / interventions tested
- Cerebrolysin — full drug profile →
Conditions studied
- Acute Ischemic Stroke — all drugs for Acute Ischemic Stroke →
Sponsor
Poznan University of Medical Sciences
Who can join
18 and older, any sex, with Acute Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study investigates whether Cerebrolysin stabilizes blood-brain barrier integrity in a manner that can be monitored using serum levels of the principal tight junction proteins, e.g., occludin (OCL), claudin-5 (CLN), and zonula occludens-1 (ZO-1), or other molecules known to be involved in BBB degradation, e.g., S100B and whether it protects against hemorrhagic transformation in ischemic stroke patients after reperfusion therapy (i.e. thrombolysis and/or mechanical thrombectomy).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06078215
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Cerebrolysin
Trials testing the same drug.
- NCT06339411 — Exploring Cerebrolysin in Late Thrombectomy for Stroke: Blood-brain Barrier Biomarkers and Imaging Insights · EARLY_PHASE1 · not yet recruiting
- NCT06677502 — Cerebrolysin in Critically Ill Patients With Delirium · NA · enrolling by invitation
- NCT05755997 — CERebrolysin In CADASIL · Phase 2 · active not recruiting
- NCT06070753 — A Prospective, Trial About Safety and Efficacy of Combined Treatment With Cerebrolysin in Acute Ischemic Hemispheric Str · NA · unknown
- NCT06052787 — Combined Cerebrolysin and Amantadine Sulfate Administration for Patients With Traumatic Brain Injury in the ICU · Phase 3 · completed
Other recruiting trials for Acute Ischemic Stroke
Currently open trials in the same condition.
- NCT07115940 — Medical Management With Endovascular Thrombectomy Versus Medical Management Alone in Patients Presenting Beyond 24 Hours · NA · recruiting
- NCT07404852 — Non-invasive Vagus Nerve Stimulation to Reduce Inflammation and Brain Injury Blood Biomarkers Following an Acute Ischemi · NA · recruiting
- NCT07361302 — A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Pe · Phase 3 · recruiting
- NCT07436156 — SUMMIT RISE Study of Acute Ischemic Stroke Patients · Phase 4 · recruiting
- NCT07203625 — Tenecteplase Before Interhospital Transfer in Acute Basilar Artery Occlusion at 4.5 to 24 Hours · Phase 4 · recruiting
Other Poznan University of Medical Sciences trials
Trials by the same sponsor.
- NCT07449468 — PENG Block and Delirium After Hip Arthroplasty · NA · not yet recruiting
- NCT07449442 — SII Levels Following iPACK Block With Adductor Canal Block in Knee Arthroplasty · NA · not yet recruiting
- NCT07474896 — Diaphragm-Sparing Regional Anesthesia Techniques for Shoulder Surgery · NA · not yet recruiting
- NCT07474909 — Perineural vs Intravenous Dexamethasone as an Adjuvant to Brachial Plexus Block in Pediatric Hand Surgery · NA · not yet recruiting
- NCT07449403 — SII Levels Following PENG Block in Hip Arthroplasty · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06078215 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Poznan University of Medical Sciences
- Last refreshed: 13 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06078215.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing